|
Market Closed -
Nasdaq
23:00:00 30/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 41.92 USD | +0.19% |
|
+3.00% | -15.65% |
| 10-30 | Supernus Pharmaceuticals, Inc., Q3 2026 Earnings Call, Oct 29, 2026 | |
| 10-30 | Earnings Flash (SUPN) Supernus Pharmaceuticals Posts Q3 EPS $0.35, vs. FactSet Est of $0.08 Loss | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 2.44B | - | - | - | ||
| 1,263B | |||||
| 658B | |||||
| 521B | |||||
| 391B | |||||
| 369B |
Select your edition
All financial news and data tailored to specific country editions
